The danger of nephrolithiasis related with atazanavir isn't very much described. The US Food and Drug Administration's Adverse Event Reporting System was looked for reports of nephrolithiasis in HIV-tainted patients taking an atazanavir-based routine. Thirty cases were recognized. Numerous patients required hospitalization for the board, including lithotripsy, ureteral stent addition, or endoscopic stone evacuation. A few instances of nephrolithiasis came about in atazanavir cessation. Medical services experts and patients should be educated that nephrolithiasis is a potential unfriendly occasion with atazanavir. The Adverse Event Reporting System (AERS) of the US Food and Drug Administration (FDA) is a deliberate detailing framework. This data set contains unconstrained reports produced by wellbeing experts, shoppers, and makers from the United States and different nations. The AERS was looked for reports of nephrolithiasis in HIV-contaminated patients taking an atazanavir-based routine. The hunt was led involving the Medical Dictionary for Regulatory Activities undeniable level term 'renal lithiasis'. This term incorporates three favoured terms: 'nephrolithiasis', 'nephrocalcinosis', and 'stag horn math'. Information on socioeconomics, co-morbidities, simultaneous meds, atazanavir openness. Demonstrative assessment (radiology, research facility results, and stone investigation), patient administration, and clinical results were evaluated for each case.